Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
Nature Genetics|September 19, 2018
Mutational processes shape the landscape of TP53 mutations in human cancerAndrew O Giacomelli, Xiaoping Yang, Robert E Lintner, et al.Cell Reports|October 3, 2019
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven CancersRita Sulahian, Jason J Kwon, Katherine H Walsh, et al.Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.Cell Reports|November 21, 2019
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerJustin H Hwang, Ji-Heui Seo, Michael L Beshiri, et al.Molecular Cancer Research : MCR|August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerElizabeth H Stover, Maria B Baco, Ofir Cohen, et al.Cell Reports|December 16, 2020
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16qJasper E Neggers, Brenton R Paolella, Adhana Asfaw, et al.Cancer Cell|September 24, 2019
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Vivian M Liu, Daniel Rosebrock, et al.Nature Communications|June 5, 2019
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastomaPratiti Bandopadhayay, Federica Piccioni, Ryan O'Rourke, et al.Nature Communications|February 2, 2022
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formationPrasidda Khadka, Zachary J Reitman, Sophie Lu, et al.Cell|December 2, 2017
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 ProfilesAravind Subramanian, Rajiv Narayan, Steven M Corsello, et al.Pageof 8